Heartburn drug Zantac recalled as FDA investigates probable carcinogen
The FDA has not recommend people stop taking the drug. However, the agency said people who want to discontinue prescriptions should talk to their doctor or pharmacist.
Sanofi said Friday it will recall the widely-used heartburn drug Zantac from stores in the United States and Canada as the drugmaker and Food and Drug Administration investigatea probable carcinogen detected in the drug.
The FDA last month said it discovered a probable carcinogencalled NDMA, or nitrosodimethylamine, in the drug Zantac and its generic versions. The FDA, Canadian and European drug regulators are evaluating possible risk to millions of people who take ranitidine, the active ingredient in Zantac and its generic versions.
”Due to inconsistencies in preliminary test results of the active ingredient used in the U.S. and Canadian products,Sanofi has made the decision to conduct the voluntary recall in the U.S. and Canada as the investigation continues,” the company said in a statement.
The FDA said preliminarytestsdetected levelsof NDMA that equal or slightly exceedthe amounts found in foods such as cured and grilled meats.
The FDA has not recommend people stop taking the drug. However, the agency said people who want to discontinue prescriptions should talk to their doctor or pharmacist. Consumers who buy non-prescription versions can switch to other over-the-counter drugs;there are multiple drugs available for the same or similar uses, the FDA said.
The FDA began evaluatingranitidine afterNew Haven, Connecticut-basedValisure, an online pharmacy,notified the agency that itstesting foundZantac and generic versions containedNDMA levels significantly higher than the FDA’s recommended daily limits. That prompted the FDA to conduct its own tests of the drugs. It did not find the same levels of the probable carcinogen that Valisure did, but the levels were high enough to warrant followup testing.